• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Syneos Health Appoints Michael Bonello as Chief Financial Officer

    5/2/23 6:19:59 AM ET
    $SYNH
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $SYNH alert in real time by email

    MORRISVILLE, N.C., May 02, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of Michael Bonello as Chief Financial Officer, effective July 1, 2023. Stanford (Ben) Rudnick will continue to serve as Interim Chief Financial Officer until that time.

    Mr. Bonello has more than 30 years of financial leadership experience, including 15 years in the clinical research industry. He most recently served as Chief Financial Officer of Clario, Inc., a clinical trial data collection company, since 2021. From 2008 to 2021, Mr. Bonello held roles of increasing responsibility at Nasdaq-listed PRA Health Sciences, Inc., including Executive Vice President and Chief Financial Officer from 2018 through the company's sale to ICON plc, and previously as Senior Vice President, Accounting and Corporate Controller from 2008 to 2018. Earlier in his career, he held financial leadership roles at Cree, Inc. and Genworth Financial, and was a senior manager in the audit practice at PricewaterhouseCoopers LLP. Mr. Bonello is a certified public accountant.

    "With decades of relevant finance expertise – and significant clinical research industry experience – Mike is ideally suited to serve as our next Chief Financial Officer. As we further transform Syneos Health for the technology and data-powered future of clinical development and commercialization, I look forward to working with Mike and our entire team to execute on our growth, innovation and efficiency goals," said Michelle Keefe, CEO of Syneos Health.  

    "Syneos Health is well regarded for its integrated strategy and leading solutions supporting customers' development and commercialization objectives," Mr. Bonello said. "I am excited to partner with Michelle, the rest of the management team and the talented employees across the organization to drive growth and value for all stakeholders."

    About Michael Bonello

    Mr. Bonello previously served as the Chief Financial Officer of Clario, Inc., a clinical trial data collection company, from November 2021 to present. Prior to that role, from May 2018 to August 2021, he served as Executive Vice President and Chief Financial Officer of PRA Health Sciences, Inc. ("PRA"), a former contract research organization that was acquired by ICON plc in 2021. Mr. Bonello previously served as Senior Vice President, Accounting and Corporate Controller for PRA, after having joined the company in March 2008. Prior to PRA, Mr. Bonello held positions with Cree, Inc., where he was Director of Finance/Corporate Controller, and Genworth Financial (formerly GE Mortgage Insurance Corporation) where he served as Vice President, Domestic Controller and Global Reporting Leader. Mr. Bonello also served for seven years in the audit practice at PricewaterhouseCoopers LLP. He received a B.B.A. with a concentration in accounting from St. Bonaventure University.

    About Syneos Health

    Syneos Health® (NASDAQ:SYNH) is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.

    We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics.

    Together we share insights, use the latest technologies and apply advanced business practices to speed our customers' delivery of important therapies to patients.

    Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.

    To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.

    Forward-Looking Statements

    Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statement's regarding our future financial results, transformation efforts and strategy. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include, but are not limited to: the Company's potential failure to generate a large number of new business awards and the risk of delay, termination, reduction in scope, or failure to go to contract of our business awards; the Company's potential failure to convert backlog to revenue; fluctuations in the Company's operating results and effective income tax rate; and other risk factors set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022 as updated by the Company's other SEC filings, copies of which are available free of charge on the Company's website at investor.syneoshealth.com. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

    Investor Relations Contact

    Ronnie Speight

    Senior Vice President, Investor Relations

    +1 919 745 2745

    [email protected]

    Media Contact

    Gary Gatyas

    Executive Director, External Communications

    +1 908 763 3428

    [email protected]



    Primary Logo

    Get the next $SYNH alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SYNH

    DatePrice TargetRatingAnalyst
    2/13/2023$30.00 → $28.00Neutral → Underweight
    JP Morgan
    1/17/2023$30.00 → $25.00Overweight → Underweight
    Barclays
    1/13/2023$25.00Overweight → Underweight
    Barclays
    12/14/2022$66.00 → $38.00Buy → Neutral
    Mizuho
    11/7/2022$55.00 → $27.00Outperform → In-line
    Evercore ISI
    10/18/2022$85.00 → $53.00Overweight → Neutral
    JP Morgan
    9/14/2022Buy → Neutral
    Guggenheim
    9/7/2022$68.00Neutral
    UBS
    More analyst ratings

    $SYNH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S.

      JERSEY CITY, N.J., April 29, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in the United States (U.S.). In 2016, MTPA was created as a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), with the goal of developing and advancing the company's pipeline in the U.S. while focusing on improving research in the areas of amyotrophic lateral sclerosis (ALS), erythropoietic protoporphyria (EPP), Parkinson's disease, spinal cord injury and systemic sclerosis. "For almost a decade, MT

      4/29/24 9:00:00 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting

      Presentations span Parkinson's disease and ALS clinical and real-world evidence Oral platform sessions will highlight results from Phase 3 BouNDless trial in PD and real-world findings from preliminary analysis of RADICAVA® (edaravone) treatment in ALSJERSEY CITY, N.J., April 12, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced seven presentations will be shared at the American Academy of Neurology (AAN) 2024 Annual Meeting being held in Denver, Colo., Apr.13-18, 2024. The presentations will discuss four abstracts in Parkinson's disease (PD) and three in amyotrophic lateral sclerosis (ALS).

      4/12/24 9:00:00 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone)

      Orphan Drug Exclusivity recognized for RADICAVA ORS based on major contribution to patient care  JERSEY CITY, N.J., April 8, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that the U.S. Food and Drug Administration (FDA) has recognized seven years of Orphan Drug Exclusivity (ODE) for RADICAVA ORS® (edaravone) based on their assessment that the oral form of edaravone constitutes a major contribution to patient care for people living with amyotrophic lateral sclerosis (ALS). The FDA's Orphan Drug program is designed to support the development of drugs that treat rare diseases which affect less than 200,000 people in the U.S. Previously, the FDA granted RADIC

      4/8/24 9:00:00 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SYNH
    SEC Filings

    See more
    • SEC Form 15-12G filed by Syneos Health Inc.

      15-12G - Syneos Health, Inc. (0001610950) (Filer)

      10/10/23 6:08:58 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 8-K filed by Syneos Health Inc.

      8-K - Syneos Health, Inc. (0001610950) (Filer)

      10/3/23 8:12:59 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form S-8 POS filed by Syneos Health Inc.

      S-8 POS - Syneos Health, Inc. (0001610950) (Filer)

      9/28/23 12:32:55 PM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SYNH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Syneos Health downgraded by JP Morgan with a new price target

      JP Morgan downgraded Syneos Health from Neutral to Underweight and set a new price target of $28.00 from $30.00 previously

      2/13/23 7:39:42 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Syneos Health downgraded by Barclays with a new price target

      Barclays downgraded Syneos Health from Overweight to Underweight and set a new price target of $25.00 from $30.00 previously

      1/17/23 9:22:20 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Syneos Health downgraded by Barclays with a new price target

      Barclays downgraded Syneos Health from Overweight to Underweight and set a new price target of $25.00

      1/13/23 9:04:42 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SYNH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Zulueta Alfonso G returned $150,199 worth of shares to the company (8,356 units at $17.97), closing all direct ownership in the company (SEC Form 4)

      4 - Syneos Health, Inc. (0001610950) (Issuer)

      9/28/23 5:08:43 PM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Wilkes David S. returned $213,839 worth of shares to the company (9,836 units at $21.74), closing all direct ownership in the company (SEC Form 4)

      4 - Syneos Health, Inc. (0001610950) (Issuer)

      9/28/23 5:08:14 PM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Monaghan Matthew E. returned $850,411 worth of shares to the company (24,640 units at $34.51), closing all direct ownership in the company (SEC Form 4)

      4 - Syneos Health, Inc. (0001610950) (Issuer)

      9/28/23 5:07:50 PM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SYNH
    Leadership Updates

    Live Leadership Updates

    See more
    • NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and

      2/27/24 9:00:00 AM ET
      $BMRN
      $ENOV
      $OPCH
      $SYNH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services
    • Civitas Resources Set to Join S&P MidCap 400; Hayward Holdings to Join S&P SmallCap 600

      NEW YORK, Sept. 26, 2023 /PRNewswire/ -- S&P SmallCap 600 constituent Civitas Resources Inc. (NYSE:CIVI) will replace Syneos Health Inc. (NASD: SYNH) in the S&P MidCap 400, and Hayward Holdings Inc. (NYSE:HAYW) will replace Civitas Resources in the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 29. Elliot Investment Management is acquiring Syneos Health in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector September 29, 2023 S&P MidCap 400 Addition Civitas Resources

      9/26/23 5:41:00 PM ET
      $CIVI
      $HAYW
      $SPGI
      $SYNH
      Oil & Gas Production
      Energy
      Industrial Machinery/Components
      Industrials
    • Syneos Health Names Terttu Haring President, Clinical Sites & Patients

      MORRISVILLE, N.C., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, has announced the appointment of Terttu Haring, MD, as President, Clinical Sites & Patients. With nearly 30 years of experience, Dr. Haring will lead the global clinical operations organization to drive exceptional delivery, quality and data integrity for customers, while ensuring a positive experience for sponsors, sites and patients. Her investigator background, and technology and data experience, will empower the Clinical Sites & Patients team to execute data-driven solutions that produce strong results for customers. Under Dr. Haring'

      9/26/23 7:30:00 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SYNH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $SYNH
    Financials

    Live finance-specific insights

    See more
    • SEC Form SC 13G/A filed by Syneos Health Inc. (Amendment)

      SC 13G/A - Syneos Health, Inc. (0001610950) (Subject)

      6/9/23 10:14:20 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by Syneos Health Inc. (Amendment)

      SC 13G/A - Syneos Health, Inc. (0001610950) (Subject)

      2/6/23 2:58:20 PM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by Syneos Health Inc. (Amendment)

      SC 13G/A - Syneos Health, Inc. (0001610950) (Subject)

      1/23/23 3:52:32 PM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Syneos Health Stockholders Approve Agreement with Private Investment Consortium

      MORRISVILLE, N.C., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (NASDAQ:SYNH) ("Syneos Health" or the "Company"), a leading fully integrated biopharmaceutical solutions organization, today announced that the Company's stockholders approved an agreement to take the Company private through an acquisition by a consortium of private investment firm affiliates comprised of Elliott Investment Management L.P., Patient Square Capital, and Veritas Capital at a special meeting of stockholders held earlier today. As previously announced, under the terms of the agreement, Syneos Health stockholders will receive $43.00 in cash for each share of Syneos Health common stock owned at the closing o

      8/2/23 8:47:45 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Syneos Health to be Acquired by a Private Investment Consortium for Approximately $7.1 Billion

      Shareholders to Receive $43.00 Per Share in Cash Represents 24% Premium to Unaffected Stock Price MORRISVILLE, N.C., May 10, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (NASDAQ:SYNH) ("Syneos Health" or the "Company"), a leading fully integrated biopharmaceutical solutions organization, today announced that it has entered into a definitive agreement to be acquired by a consortium of private investment firm affiliates composed of Elliott Investment Management ("Elliott"), Patient Square Capital ("Patient Square"), and Veritas Capital ("Veritas") for $43.00 per share in cash in a transaction valued at approximately $7.1 billion, including outstanding debt. The purchase price represents a

      5/10/23 6:47:41 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Syneos Health Schedules First Quarter 2023 Earnings Call for Wednesday, May 10th, 2023

      MORRISVILLE, N.C., April 13, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, will release its first quarter 2023 financial results on Wednesday, May 10th, 2023, prior to its earnings call at 8:00 a.m. ET. To listen only and view the presentation slides via the live webcast, join from the Investor Relations section of the Syneos Health website at investor.syneoshealth.com. To participate in the conference, please register in advance at this link. Upon registration, all participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a uni

      4/13/23 4:31:00 PM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care